Innodata Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Innodata Inc trades at $60.7 (market cap $2.10B), while Roivant Sciences Ltd. Common Shares trades at $34.49 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 11.8× Innodata Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| INOD | ROIV | |
|---|---|---|
Market Cap | $2.10B | $24.72B |
Volume | 989,493 | 6,279,442 |
Sector | Technology | Health |
52-Week High | $121.50 | $41.81 |
52-Week Low | $34.45 | $16.04 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $1.86B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $63.42, down 4.26% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The company shows robust profitability with 42.7% gross margins and 37.7% ROE, while technical indicators suggest a bullish trend despite recent pullback. Recent developments include expansion into motion-capture AI labs and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive with analyst consensus favoring buy ratings (66.7%) and projected revenue growth to $317M in 2026. Key risks include premium valuation metrics (P/E 47.4) and customer concentration concerns, but strong cash flow generation and expanding AI service offerings provide growth catalysts for investors seeking exposure to the data engineering sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →